SOAN FIRST TITAN CORP

AngioSoma Launching Holiday Awareness Campaign

AngioSoma Launching Holiday Awareness Campaign

Heart Health Focused Campaign Set to Kick Off December 1st, 2018

HOUSTON, TX, Nov. 12, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – AngioSoma (OTC: SOAN), a leading biotechnology research and development company, announces today a new campaign is in production to bring awareness to a range of heart health issues.

AngioSoma is the producer of Liprostin™, a flagship patented pharmaceutical intervention for Peripheral Artery Disease. Currently, 8.5 million people in the United States suffer from this deadly disease and Liprostin™, presently in the approval process of the FDA, is a good alternative treatment for some patients.   The awareness campaign will focus on Peripheral Artery Disease, plus other forms of heart disease, with a focus on prevention and early detection.

“The more information people have the earlier heart problems can be identified,” said Alex Blankenship, President of AngioSoma. “Outcomes for patients are much better with early detection and our campaign is focused on this, plus making good lifestyle choices to reduce the risk of developing heart problems.”

The campaign will start December 1, 2018 and will include Facebook, Twitter, and Instagram social channels as well as supporting website content.

You can view and purchase our products on Amazon.com: 

Also, products can be found on our ecommerce site: YouthfulBrilliance.com.

ABOUT ANGIOSOMA, INC.

AngioSoma, Inc. (), a Nevada corporation based in Houston, Texas is dedicated to improving the mental and physical wellbeing of men and women. To accomplish that purpose, we are launching a line of supplements under our SomaCeuticals™ common identity. Our supplements cover three industry segments: nutraceuticals, cosmeceuticals, and pharmaceuticals.

NOTICE REGARDING FORWARD LOOKING STATEMENTS

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.

Contacts

AngioSoma, Inc.
Alex Blankenship
EN
12/11/2018

Underlying

SOANFIRST TITAN CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FIRST TITAN CORP

 PRESS RELEASE
Free
SOAN FIRST TITAN COR...

AngioSoma and its Subsidiary SomaCeuticals Announce Amended and Restat...

AngioSoma and its Subsidiary SomaCeuticals Announce Amended and Restated Execution of Global License for Multiple Sclerosis Patent Houston, TX, Feb. 11, 2021 (GLOBE NEWSWIRE) --  -- AngioSoma Inc. (: SOAN) (“AngioSoma” or the “Company”), through its wholly-owned subsidiary, SomaCeuticals, Inc., is pleased to announce that the Exclusive Global Multiple Sclerosis License Agreement dated August 23, 2020 has been amended and restated as of February 4, 2021 to give both parties a stronger and more robust platform to move synergistically forward to market and license Patent 10,619,592 issued to...

February 11, 2021 1 EN
 PRESS RELEASE
Free
SOAN FIRST TITAN COR...

SomaCeuticals Moving Forward With Treatment of Multiple Sclerosis

SomaCeuticals Moving Forward With Treatment of Multiple Sclerosis Houston, Dec. 08, 2020 (GLOBE NEWSWIRE) -- via -- AngioSoma Inc. (: SOAN) (“AngioSoma” or the “Company”) is pleased to announce that the Company’s subsidiary, SomaCeuticals, Inc., has defined its mission to bring its enhanced treatment for Multiple Sclerosis to patients worldwide.   After an intensive search, the Company has identified a well-known firm with a capable team that may be engaged to help with regulatory clearance of the treatment for worldwide treatment of patients. The treatment is encouraged by t...

December 8, 2020 1 EN
 PRESS RELEASE
Free
SOAN FIRST TITAN COR...

SomaCeuticals Acquires License for Treatment of Multiple Sclerosis

SomaCeuticals Acquires License for Treatment of Multiple Sclerosis Houston, TX, Aug. 24, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma Inc. (: SOAN) (“AngioSoma” or the “Company”) is pleased to announce that the company’s subsidiary, SomaCeuticals, Inc., has executed a licensing agreement with 7 to Stand, Inc. (a Delaware corporation) for the exclusive global rights to U.S. patent 10,610,592 issued to Fabrizio de Silvestri, Terni, Italy, as inventor, April 7, 2020 for treatment of Multiple Sclerosis (MS). Multiple Sclerosis (MS) is a chronic disease in which the immune system ...

August 24, 2020 1 EN
 PRESS RELEASE
Free
SOAN FIRST TITAN COR...

SomaCeuticals Elects New President

SomaCeuticals Elects New President Houston, TX, Aug. 17, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma Inc. (: SOAN) (“AngioSoma” or the “Company”) is pleased to announce that the company’s subsidiary, SomaCeuticals, Inc., has elected James C. Katzaroff as President to serve until his successor is elected and qualified. Mr. Katzaroff is in discussions with the holder of a patented treatment for Multiple Sclerosis with the intent to negotiate an exclusive perpetual license. Mr. Katzaroff is the founder of Advanced Medical Isotope Corp. (now known as Radiogel) and was the Chairm...

August 17, 2020 1 EN
 PRESS RELEASE
Free
SOAN FIRST TITAN COR...

AngioSoma Focusing on Development of Coating for Metal Stents

AngioSoma Focusing on Development of Coating for Metal Stents Houston, TX, May 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma, Inc. (: SOAN) (“AngioSoma” or the “Company”) is pleased to announce that the Company is focusing on development and commercialization of our coating for metal stents.  A stent is an expandable “scaffold-like” device, usually constructed of a metallic material, that is inserted into an artery to expand the inside passage and improve blood flow for prevention of vascular restenosis and treatment of complex vascular and coronary disease.  A bifurcated ver...

May 27, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch